The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| TVTX | +42.08% | -4.8% | -0.98% | +470% |
| S&P | +16.64% | +82.26% | +12.76% | +380% |
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.
This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments.
A regulatory decision on a top investigational drug won't be coming as soon as hoped.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $129.69M | 73.4% |
| Gross Profit | $109.00M | 81.2% |
| Gross Margin | 84.05% | 3.6% |
| Market Cap | $3.42B | 125.5% |
| Market Cap / Employee | $6.88M | 0.0% |
| Employees | 497 | 29.1% |
| Net Income | -$21,986.00K | 63.5% |
| EBITDA | -$14,291.00K | 69.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $93.04M | 58.9% |
| Accounts Receivable | $80.13M | 195.5% |
| Inventory | 5.9 | -5.2% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $322.86M | -1.4% |
| Short Term Debt | $5.88M | -92.1% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -8.38% | 38.0% |
| Return On Invested Capital | -57.86% | -9.8% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $61.05M | 271.3% |
| Operating Free Cash Flow | $60.68M | 269.9% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 26.53 | 40.03 | 65.03 | 46.47 | -204.26% |
| Price to Sales | 5.79 | 3.94 | 5.63 | 7.03 | 13.24% |
| Price to Tangible Book Value | -34.91 | -18.51 | -29.23 | -95.29 | 845.47% |
| Price to Free Cash Flow TTM | 91.31 | - | |||
| Enterprise Value to EBITDA | -55.62 | 1022.28 | 62.08 | -241.83 | 672.67% |
| Free Cash Flow Yield | 1.1% | - | |||
| Return on Equity | -422.7% | -705.7% | -410.8% | -57.8% | -76.57% |
| Total Debt | $400.46M | $399.57M | $329.75M | $328.73M | -18.14% |
No podcast episodes available.
RTRX earnings call for the period ending March 31, 2020.
RTRX earnings call for the period ending December 31, 2019.
RTRX earnings call for the period ending September 30, 2019.
RTRX earnings call for the period ending June 30, 2019.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
